Hartland & Co »

Inhibikase Therapeutics shares owned by Hartland & Co

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Hartland & Co from 13F filings

Historical chart of Hartland & Co investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Hartland & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Hartland & Co

Quarter filed Position value Share count Share price at filing
2026-06-30 $13 6 2.17

More positions owned by Hartland & Co

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core S&p500 Etf (IVV)
Apple Put Put Option (Principal) (AAPL)
Paccar (PCAR)
Ishares Tr Rus 1000 Grw Etf (IWF)
Vanguard Index Fds Mid Cap Etf (VO)
Microsoft Corporation (MSFT)
Vanguard Index Fds Small Cp Etf (VB)
Vanguard Index Fds Value Etf (VTV)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Spdr Index Shs Fds St Str Po Ex Etf (SPDW)
Amazon Call Call Option (AMZN)
Vanguard Scottsdale Fds Mtg-bkd Secs Etf (VMBS)
Ishares Tr Core Msci Intl (IDEV)
Vanguard Index Fds Call Call Option (VTI)

View all positions for Hartland & Co

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Trails Edge Capital Partners
Fairmount Funds Management
BlackRock
ADAR1 Capital Management
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Millennium Management
Saturn V Capital Management
Kalehua Capital Management
Spruce Street Capital
Squadron Capital Management

View all funds holding Inhibikase Therapeutics